NASOPHARYNGEAL CARCINOMA
Clinical trials for NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control returning nose cancer
Disease control Not yet recruitingThis study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial therapy. First, patients receive a targeted drug (MRG003) plus an immunotherapy (tislelizumab) for six weeks. Then they switch to a chemotherapy pill (capecitabine) plus the s…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
Promising new combo targets hard-to-treat throat cancer recurrence
Disease control Not yet recruitingThis study tests a new treatment for people whose nasopharyngeal cancer has come back and cannot be removed by surgery. Participants will receive two cycles of a targeted drug (becotatug vedotin) plus an immunotherapy (PD-1 inhibitor), followed by radiation therapy and continued …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug cocktail aims to shrink Hard-to-Treat head and neck tumors
Disease control Not yet recruitingThis study tests a combination of three drugs (chidamide, toripalimab, and anlotinib) in people with nasopharyngeal cancer that has returned or spread and no longer responds to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New drug combo aims to stop advanced nose cancer from coming back
Disease control Not yet recruitingThis study tests whether adding an immunotherapy drug (PD-1 antibody) and a targeted therapy (anlotinib) to standard chemoradiation can help prevent high-risk nasopharyngeal cancer from returning. About 442 adults with stage III disease will receive either the new combination or …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New study aims to unlock Cancer's genetic secrets
Knowledge-focused Not yet recruitingThis study looks for biological markers in people with nasopharyngeal carcinoma, a type of head and neck cancer. Researchers will analyze tissue samples to find patterns that may help predict how the disease will progress. The goal is to improve future treatment decisions, not to…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC
-
New study aims to find best next step for tough nasopharyngeal cancer cases
Knowledge-focused Not yet recruitingThis study looks at two different treatment paths for people with advanced nasopharyngeal cancer whose tumors did not shrink enough after two rounds of chemotherapy. One group will get a different type of chemotherapy followed by radiation, while the other group will go straight …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Sponsor: Fujian Cancer Hospital • Aim: Knowledge-focused
Last updated May 14, 2026 12:01 UTC